Biotech BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS April 9, 2024
Biotech Immunovia successfully develops assays to measure targeted proteins for its next-generation pancreatic cancer test – moving forward towards model-development study April 9, 2024
Biotech Global Antibody Discovery Market Valuation Set to Total US$ 21.8 Billion by 2034, Spurred by Escalating Demand for Targeted Therapies April 8, 2024
Biotech Servier Data Presented at AACR Underscores Unwavering Dedication to Advancing Oncology R&D April 8, 2024
Biotech Clover Announces Positive Preliminary Phase I Results for Bivalent RSV Vaccine Candidate SCB-1019 in Initial Young Adult Cohort April 8, 2024
Biotech CARVYKTI® is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy April 6, 2024
Biotech Asep Joint Venture Company, SepSMART, obtains Business License and is Formally Registered in China April 6, 2024
Search
Biotech
April 9, 2024
April 9, 2024
April 9, 2024
April 8, 2024
April 8, 2024
April 8, 2024
April 8, 2024
April 6, 2024
April 6, 2024
April 6, 2024
